WO2007054453A3 - Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa - Google Patents

Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa Download PDF

Info

Publication number
WO2007054453A3
WO2007054453A3 PCT/EP2006/068012 EP2006068012W WO2007054453A3 WO 2007054453 A3 WO2007054453 A3 WO 2007054453A3 EP 2006068012 W EP2006068012 W EP 2006068012W WO 2007054453 A3 WO2007054453 A3 WO 2007054453A3
Authority
WO
WIPO (PCT)
Prior art keywords
coagulation factor
cyclic amines
inhibitors
fused cyclic
carbocyclic fused
Prior art date
Application number
PCT/EP2006/068012
Other languages
French (fr)
Other versions
WO2007054453A2 (en
Inventor
Markus Boehringer
Zbinden Katrin Groebke
Wolfgang Haap
Narendra Panday
Fabienne Ricklin
Martin Stahl
Petra Schmitz
Original Assignee
Hoffmann La Roche
Markus Boehringer
Zbinden Katrin Groebke
Wolfgang Haap
Narendra Panday
Fabienne Ricklin
Martin Stahl
Petra Schmitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Markus Boehringer, Zbinden Katrin Groebke, Wolfgang Haap, Narendra Panday, Fabienne Ricklin, Martin Stahl, Petra Schmitz filed Critical Hoffmann La Roche
Priority to EP06829926A priority Critical patent/EP1948639A2/en
Priority to AU2006311101A priority patent/AU2006311101A1/en
Priority to CA002627426A priority patent/CA2627426A1/en
Priority to JP2008539402A priority patent/JP4955009B2/en
Priority to BRPI0618523-1A priority patent/BRPI0618523A2/en
Publication of WO2007054453A2 publication Critical patent/WO2007054453A2/en
Publication of WO2007054453A3 publication Critical patent/WO2007054453A3/en
Priority to IL190909A priority patent/IL190909A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The invention is concerned with novel carbocyclyl fused cyclic amines of formula (I) wherein A, X1 to X3, Y1 to Y3, Z, R1, R2, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit the coagulation factor Xa and can be used as medicaments.
PCT/EP2006/068012 2005-11-11 2006-11-01 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa WO2007054453A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06829926A EP1948639A2 (en) 2005-11-11 2006-11-01 Novel carbocyclic fused cyclic amines
AU2006311101A AU2006311101A1 (en) 2005-11-11 2006-11-01 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor Xa
CA002627426A CA2627426A1 (en) 2005-11-11 2006-11-01 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
JP2008539402A JP4955009B2 (en) 2005-11-11 2006-11-01 Carbocyclic fused ring amines as inhibitors of coagulation factor Xa
BRPI0618523-1A BRPI0618523A2 (en) 2005-11-11 2006-11-01 carbocyclically fused cyclic amine compounds, pharmaceutical compositions and uses thereof
IL190909A IL190909A0 (en) 2005-11-11 2008-04-16 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05110635.9 2005-11-11
EP05110635 2005-11-11

Publications (2)

Publication Number Publication Date
WO2007054453A2 WO2007054453A2 (en) 2007-05-18
WO2007054453A3 true WO2007054453A3 (en) 2007-07-19

Family

ID=37730317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/068012 WO2007054453A2 (en) 2005-11-11 2006-11-01 Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa

Country Status (10)

Country Link
US (2) US20070112012A1 (en)
EP (1) EP1948639A2 (en)
JP (1) JP4955009B2 (en)
KR (1) KR20080067697A (en)
CN (1) CN101304989A (en)
AU (1) AU2006311101A1 (en)
BR (1) BRPI0618523A2 (en)
CA (1) CA2627426A1 (en)
IL (1) IL190909A0 (en)
WO (1) WO2007054453A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550487B2 (en) * 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
ZA200701232B (en) 2004-07-15 2008-08-27 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP2060564A1 (en) * 2007-11-19 2009-05-20 Ludwig-Maximilians-Universität München Non-peptidic promoters of apoptosis
JP5385297B2 (en) 2007-11-22 2014-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New compounds
EP2062889A1 (en) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Compounds
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN102638982B (en) 2009-05-12 2015-07-08 百时美施贵宝公司 Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
KR20120034644A (en) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
CA2760837C (en) * 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CN103313968A (en) 2010-11-15 2013-09-18 Abbvie公司 Nampt and rock inhibitors
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN103987697B (en) 2011-10-14 2017-04-26 百时美施贵宝公司 Substituted tetrahydroisoquinoline compounds as factor XIA inhibitors
SG11201401384UA (en) 2011-10-14 2014-09-26 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059214A1 (en) * 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN104837833B (en) * 2012-10-12 2017-07-14 百时美施贵宝公司 The crystal formation of XIA factor inhibitors
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
CA2890002A1 (en) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
ES2712699T3 (en) * 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahydroisoquinolines containing substituted azoles as inhibitors of factor XIa
MY186311A (en) 2013-12-20 2021-07-08 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
CN116987080A (en) 2014-01-31 2023-11-03 百时美施贵宝公司 Macrocyclic compounds with heterocyclic P2' groups as factor XIA inhibitors
NO2760821T3 (en) 2014-01-31 2018-03-10
JP6526796B2 (en) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Diamide macrocycles that are FXIA inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6862368B2 (en) * 2015-06-25 2021-04-21 プロメガ コーポレイションＰｒｏｍｅｇａ Ｃｏｒｐｏｒａｔｉｏｎ Use as an inhibitor of thienopyrol compounds and their Oplophorus-derived luciferase
CN105503723A (en) * 2015-12-31 2016-04-20 赵国良 Pharmaceutical composition for treating coronary heart disease
CN107188891A (en) * 2017-06-29 2017-09-22 天津药明康德新药开发有限公司 A kind of synthetic method of 5 (tert-butyl carbonyl) 1 methylimidazoles and the carboxylic acid of pyridine 7
MX2022009524A (en) 2020-02-07 2023-01-11 Gasherbrum Bio Inc Heterocyclic glp-1 agonists.

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1004617B (en) * 1953-05-13 1957-03-21 Geigy Ag J R Process for the preparation of basic derivatives of 2-aryl indoles
FR2315270A1 (en) * 1975-06-23 1977-01-21 Delmar Chem PHENYLINDOLINES AND PROCESS FOR THEIR PRODUCTION
EP0141686A1 (en) * 1983-08-11 1985-05-15 Synthelabo Indole derivatives, their preparation and their therapeutical application
US4659731A (en) * 1985-02-08 1987-04-21 Synthelabo 2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydroindole derivatives and their application as α2 receptor antagonist or α1 receptor agonists
US4908376A (en) * 1985-09-03 1990-03-13 Ciba-Geigy Corporation 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles in composition form for reducing intraocular pressure
US5017584A (en) * 1984-12-20 1991-05-21 Sterling Drug Inc. Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas
EP0810214A1 (en) * 1995-02-17 1997-12-03 Tokyo Tanabe Company Limited Process for producing indoline compounds and intermediates for the production of the same
US5972946A (en) * 1995-04-13 1999-10-26 Dainippon Pharmaceutical Co., Ltd. Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same
EP1104754A1 (en) * 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
US20020019531A1 (en) * 1997-03-31 2002-02-14 Eisai Co., Ltd. Indoles
WO2002014277A1 (en) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
WO2004094372A2 (en) * 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Compounds useful as serine protease inhibitors
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3031458A (en) * 1958-02-05 1962-04-24 Ciba Pharm Prod Inc Isoindolines
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
US5567718A (en) * 1994-08-11 1996-10-22 Hoechst Marion Roussel Inc. 2,3-dihydro-1h-isoindole derivatives and their use as serotonin reuptake inhibitors
CA2259573A1 (en) * 1996-07-08 1998-01-15 Ruth Richmond Wexler Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of factor xa and of thrombin
JP2000143623A (en) * 1998-08-28 2000-05-26 Dai Ichi Seiyaku Co Ltd New sulfonyl derivative and its salt
AU5567000A (en) * 1999-06-24 2001-01-09 Toray Industries, Inc. Alpha1b-adrenergic receptor antagonists
US7125891B2 (en) * 2000-10-30 2006-10-24 Janssen Pharmaceutica N.V. Tripeptidyl peptidase inhibitors
EP1363890A4 (en) * 2001-02-07 2009-06-10 Ore Pharmaceuticals Inc Melanocortin-4 receptor binding compounds and methods of use thereof
DE10137163A1 (en) * 2001-07-30 2003-02-13 Bayer Ag New thiophenecarboxamido-substituted isoindole derivatives, useful as Factor XIa inhibitors for treatment or prophylaxis of, e.g. thromboembolic diseases, atherosclerosis, arthritis, Alzheimer's disease or cancer
WO2004058715A1 (en) * 2002-12-25 2004-07-15 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
KR20050118708A (en) * 2003-04-03 2005-12-19 메르크 파텐트 게엠베하 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
ES2285444T3 (en) * 2003-04-03 2007-11-16 Merck Patent Gmbh DERIVATIVES OF 1- (PHENYL) -AMIDA) -2- (PHENYL) -AMIDA) OF PIRAZOLIDIN-1,2-DICARBOXILIC ACID AS INHIBITORS OF COAGULATION FACTOR XA FOR THE TROMBOSIS TREATMENT.
JP4769082B2 (en) * 2003-12-17 2011-09-07 武田薬品工業株式会社 Urea derivatives, their production and use

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1004617B (en) * 1953-05-13 1957-03-21 Geigy Ag J R Process for the preparation of basic derivatives of 2-aryl indoles
FR2315270A1 (en) * 1975-06-23 1977-01-21 Delmar Chem PHENYLINDOLINES AND PROCESS FOR THEIR PRODUCTION
EP0141686A1 (en) * 1983-08-11 1985-05-15 Synthelabo Indole derivatives, their preparation and their therapeutical application
US5017584A (en) * 1984-12-20 1991-05-21 Sterling Drug Inc. Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas
US4659731A (en) * 1985-02-08 1987-04-21 Synthelabo 2-(4,5-Dihydro-1H-imidazol-2-yl)-2,3-dihydroindole derivatives and their application as α2 receptor antagonist or α1 receptor agonists
US4908376A (en) * 1985-09-03 1990-03-13 Ciba-Geigy Corporation 2,3-dihydro-2-(4,5-dihydroimidazol-2-yl)-indoles in composition form for reducing intraocular pressure
EP0810214A1 (en) * 1995-02-17 1997-12-03 Tokyo Tanabe Company Limited Process for producing indoline compounds and intermediates for the production of the same
US5972946A (en) * 1995-04-13 1999-10-26 Dainippon Pharmaceutical Co., Ltd. Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same
US20020019531A1 (en) * 1997-03-31 2002-02-14 Eisai Co., Ltd. Indoles
EP1104754A1 (en) * 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Novel sulfonyl derivatives
WO2002014277A1 (en) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof
WO2004094372A2 (en) * 2003-04-16 2004-11-04 Bristol-Myers Squibb Company Compounds useful as serine protease inhibitors
WO2006055951A2 (en) * 2004-11-19 2006-05-26 Portola Pharmaceuticals, Inc. Tetrahydroisoquinolines as factor xa inhibitors

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 11, 2001, GBELSEVIER SCIENCE LTD., pages 2947 - 2950, XP002421844 *
CHEM. PHARM. BULL., vol. 41, no. 5, 1993, pages 816 - 821 *
CURRAN D P ET AL: "Asymmetric radical cyclization reactions of axially chiral N-allyl-o-iodoanilides to form enantioenriched N-acyl dihydroindoles", 10 May 2004, TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, PAGE(S) 4413-4424, ISSN: 0040-4020, XP004505119 *
DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FOEDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002421853 *
DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FOEDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002421854 *
DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FOEDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; XP002421855 *
DATABASE WPI Week 200231, Derwent World Patents Index; AN 2002-269170, XP002429680 *
E. C. KORNFELD ET AL.: "The total synthesis of Lysergic acid", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 78, 1956, USAMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., pages 3087 - 3114, XP002421848 *
INDIAN J. CHEM. SECT. B, vol. 23, no. 10, 1984, pages 986 - 988 *
J. CHEM. RES. SYNOP., 1977, pages 212 *
RICARDO LIRA ET AL.: "Palladium-catalyzed synthesis of N-Aryl-2-benzylindolines...", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 126, no. 43, 2004, USAMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., pages 13906 - 13907, XP002421845 *
STEPHEN BROWN ET AL.: "Palladium catalysed queing processes.", TETRAHEDRON., vol. 57, 2001, NLELSEVIER SCIENCE PUBLISHERS, AMSTERDAM., pages 1347 - 1359, XP002421846 *
TOSHIKO KIGUCHI ET AL.: "One-pot synthesis of Indoles from 1-Benzyl-2,3-dihydroindoles", SYNTHESIS., vol. 10, 1989, DEGEORG THIEME VERLAG, STUTTGART., pages 778 - 781, XP002421847 *
WAYLAND E. NOLAND ET AL.: "Mixed Indole dimers", JOURNAL OF ORGANIC CHEMISTRY., vol. 25, 1960, USAMERICAN CHEMICAL SOCIETY. EASTON., pages 1525 - 1535, XP002421849 *

Also Published As

Publication number Publication date
CA2627426A1 (en) 2007-05-18
EP1948639A2 (en) 2008-07-30
US20070112012A1 (en) 2007-05-17
US20120122854A1 (en) 2012-05-17
KR20080067697A (en) 2008-07-21
JP4955009B2 (en) 2012-06-20
JP2009514926A (en) 2009-04-09
BRPI0618523A2 (en) 2011-09-06
AU2006311101A1 (en) 2007-05-18
CN101304989A (en) 2008-11-12
IL190909A0 (en) 2008-11-03
WO2007054453A2 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
WO2007054453A3 (en) Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
WO2006114401A3 (en) Novel cyclic amines
TW200740809A (en) Novel heteroaryl fused cyclic amines
TW200800970A (en) Novel cycloalkane carboxamides
MY146491A (en) Fused pyrrole derivatives
TW200833324A (en) Sulfonamide derivatives
WO2009021868A3 (en) Novel piperazine amide derivatives
DE602005016297D1 (en) ANTITHROMBOTIC DIAMIDE
MX2009010218A (en) Aza-pyridopyrimidinone derivatives.
WO2009013211A3 (en) New pyrazol derivatives
TW200745032A (en) Novel heterobicyclic derivatives
MX2009004441A (en) Indazole derivatives useful as l-cpt1 inhibitors.
EP1809600A4 (en) Cyclic b-amino acid derivatives as factor xa inhibitors
WO2009040289A3 (en) Biaryl sulfonamide derivatives
NO20093200L (en) thiazolidine derivatives
WO2009043747A3 (en) N-heterocyclic biaryl carboxamides as ccr receptor antagonists
ATE372767T1 (en) DPP-IV INHIBITORS
TW200633963A (en) Novel cyclohexane derivatives
MX2009010567A (en) Imidazolidinone derivatives.
TW200626527A (en) Novel hexafluoroisopropanol derivatives
IL187409A0 (en) Sulfonamide derivatives useful as liver carnitine palmitoyl transferase (l- cpt1) inhibitors
MY144101A (en) Pyrrolidine-3,4-dicarboxamide derivatives
MX2007005113A (en) Dicarboxamide derivatives and their use as factor xa inhibitors.
MX2009007416A (en) Sulfonamide derivatives as chymase inhibitors.
MX2009013003A (en) Piperidine-amide derivatives.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680042053.3

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006829926

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 190909

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2627426

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006311101

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/005844

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2301/CHENP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2008539402

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006311101

Country of ref document: AU

Date of ref document: 20061101

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006311101

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020087013809

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2006829926

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0618523

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080512